In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Jazz Pharmaceuticals plc. Trade Record

NASDAQ:JAZZ Jazz Pharmaceuticals plc stock gains 8.34% Exit Feb 28, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart JAZZ Jan 31, 2017, priceSeries
About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinson's disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.

Trade Information
Trade Type
LONG
ReliabilityScore™
95.68
Entry Date
Jan 31, 2017
Entry Price
121.92
Sell Date
Feb 28, 2017
Sell Price
132.09
Net Gain
8.34%
Hold Time
19 Trading Days